Introduction
In Poland -as in other European countries -nuclear cardiology procedures belong to most extensively performed scintigraphic studies. In the United States where nuclear cardio logy is particularly well developed, those procedures form more than 50% of all nuclear medicine procedures. A collective dose Patient exposure to ionising radiation due to nuclear medicine cardiac procedures
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The contemporary nuclear medicine applies methods for the assessment of myocardial perfusion, contractile function, metabo lism, viability, innervation, and also detection of regions of necro sis and apoptosis in myocardium. Procedures for assessment of perfusion, contractile function and metabolism gained a prominent position in clinical practice. The most frequent procedure among those listed above is assessment of myocardial perfusion.
A gamma radiation is an information carrier in radionuclide diagnostics, the quanta of this radiation are emitted by short lived radionuclides introduced into the organism by means of injected radiopharmaceuticals. The role of a radiation emitter can be played by radioactive element or by a compound containing a radioactive atom in its structure. After intravenous injection radiopharmaceuticals are taken up, cumulated and eliminated from a myocardium or travel through heart cavities. Kinetics of these processes reflect various physiological functions and may reflect and localise abnormalities resulting from diseases of the heart and circulatory system. These processes can by registered by means of external measurements using scintillation cameras, thanks to high pe netration of gamma rays through patient body. The imaging instru ments enable both planar as well as tomographic visualization of myocardium by SPECT (single photon emission tomography) modality and by PET (positron emission tomography) techniques.
(Additionally, Xrays produced by hybrid SPECT/CT and PET/CT instruments provide threedimensional tissue density maps. Ba sing on transmission data it is possible to correct for the gamma ray absorption by tissues surrounding the heart. This procedure provides more accurate data on distribution of a radiopharmaceuti cal in myocardium [2] . Due to the fact that CT scanners mounted additionally on hybrid instruments work during cardiac studies in a low dose mode, use of CT rises a radiation to a patient only slightly (more precise values will be presented later).
The most important advances of nuclear cardiology are: 
Radiation doses, health risk
A health risk to patients from radiopharmaceuticals results only from exposure to ionizing radiation -gamma rays and posi trons -when PET technique is used, which in effect of annihila tions with electrons also produce some gamma rays.
The radiation risk depends on doses absorbed by patient or gans. The absorbed dose of radiation has been defined as a ratio of energy deposited and a mass of an absorbing tissue. The unit of absorbed radiation is 1 Gray (Gy) which equals 1 Joule of energy per 1 kg of tissue. The magnitude of such a dose is usually clas sified as large when it exceeds 1 Gy; low doses are those below 0,1 Gy (100 mGy) [3] . Intermediate doses are those between the two classes defined above.
An effective dose has been defined by the ICRP (International Committee on Radiological Protection) [4] for an assessment of a risk to whole human body. This kind of dose takes into account different sensitivity of organs to radiation as well as different rela tive biological effectiveness of various kinds of ionizing radiation.
However, in case of nuclear medicine studies relative biological effectiveness of radiations used for diagnostic purposes (gamma and beta plus) is equal to one. Therefore the effective dose is a sum of the products of absorbed doses in organs and tissues and their sensitivity factors. Radiopharmaceuticals cause differenti ated exposition of organs due to inhomogeneous distribution of activity in a human body. Radiopharmaceuticals used in nuclear cardiology also show affinity for another tissues and organs, like brain, thyroid, skeletal muscles, liver. Moreover, they are trans ported with body fluids and are secreted in gastrointestinal and urinary tracts (Figure 1 ). This is why calculation of an effective dose resulting from administration of a radiopharmaceutical must take into account its distribution and kinetics in the whole body. The unit of the effective dose is named sievert [Sv] . In practice, for the assessment of the risk to patients smaller dose units are used (milisievert -0.001 Sv). Effective doses to humans from gamma and beta plus radiations emitted by radiopharmaceuticals ap plied in diagnostic cardiac procedures and, for comparison, also doses from X ray studies in several radiological procedures applied in cardiology are presented in Tables 1 and 2 . As was mentioned earlier, additional use of low dose CT during cardiac SPECT of PET studies rises a radiation to a patient only slightly, by 1-1.5 mSv [5, 6] . It can be seen that both imaging modalities (nuclear medicine and radiological) are sources of similar or slightly lower effective doses, excepting interventional procedures (like percutaneous coronary angioplasty) that can expose patients to substantially higher radiation risk.
Biological effects of ionizing radiation in a human organism can be divided into two categories: deterministic and stochastic This means that death risk from fatal cancer caused by patient irradiation during stress and rest perfusion study of myocardium (effective dose 10 mSv) could be estimated as lower than of 0.1 per mille. For better understanding of this risk: if a large population of people was exposed to analogous radiation dose, malignant neoplasms leading to death could be additionally expected in less than 0.1 pro mille of this population. One should remember that normal mortality from spontaneous malignant tumours in hu man populations amounts to 20-25% [3, 12] .
In addition, one should also remember that potential effect of the discussed nature is delayed after irradiation. The shortest delay time of radiation induced leukemia equals 2-3 years (the average delay is 7 years) and for malignant solid tumours the analogous time intervals are 10-15 years (mean 20 y) [3] .
In addition, the risk declines with age. The probability of cancer induction after exposure at the age of 60 years is 5 times lower than that after exposure at 20-40 years [3] .
The sensitivity to radiation in utero life and the first decade after birth is 2-3 times higher than that given above for the whole population [3] .
A nuclear medicine study, if conducted in a proper way and undertaken due to reasonable indications, carries potential health gains for a patient, exceeding by orders of magnitude the negative effects for health and life. In other words, refraining from a well motivated nuclear medicine procedure can be a source of incomparably higher risk to a patient.
Conclusion
Nuclear medicine diagnostic procedures, including the car diological ones, are accompanied by a very small radiation risk. 2. Optimization of patient protection, i.e. exposure to possibly low doses but providing appropriate procedure and radio pharmaceutical activity to obtain useful result; 3. Avoiding nuclear medicine procedures in pregnant women (due to higher sensitivity of the embryo and fetus to ionizing radiation), especially that in many clinical situations there is a possibility to apply in women at that age other diagnostic studies that do not expose patients to ionizing radiation (like e.g. echocardiography). 
